Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. Co.'s primary product candidate, roflumilast cream, has the potential to provide symptomatic improvement in psoriasis patients similar to the combination of a high potency steroid and calcipotriene, a tolerability profile, the ability to be used chronically, and little to none of the application site reactions associated with various existing topical treatments. Co. is also developing a foam formulation of topical roflumilast for the treatment of scalp psoriasis and seborrheic dermatitis.
ARQT SEC Filing Email Alerts Service
Company Name: |
Arcutis Biotherapeutics Inc |
Website: |
www.arcutis.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding ARQT: |
18 |
Total Market Value Held by ETFs: |
$135.31M |
Total Market Capitalization: |
$850.00M |
% of Market Cap. Held by ETFs: |
15.92% |
|
|
May 1, 2024 8:13 PM Eastern
Strong Buy (3.50 out of 4)
59th percentile
|
|